
## Marco Capezzone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1736688/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Silent thyroiditis following vaccination against COVID-19: report of two cases. Journal of Endocrinological Investigation, 2022, 45, 1079.	1.8	11
2	Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients. Frontiers in Endocrinology, 2022, 13, 845954.	1.5	3
3	Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?. Journal of Endocrinological Investigation, 2021, 44, 139-144.	1.8	0
4	Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules. Thyroid, 2021, 31, 446-451.	2.4	11
5	Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 2021, 44, 943-950.	1.8	31
6	Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma. European Thyroid Journal, 2021, 10, 295-305.	1.2	5
7	Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e855-e865.	1.8	5
8	Preliminary results from whole-genome expression analysis in patients with secondary adrenal insufficiency treated with modified-release hydrocortisone. Endocrine, 2021, 73, 177-185.	1.1	1
9	Clinical features of pediatric familial non-medullary thyroid cancer (FNMTC). Journal of Endocrinological Investigation, 2021, 44, 2319-2321.	1.8	2
10	The Combination of Sonographic Features and the Seven-Gene Panel May be Useful in the Management of Thyroid Nodules With Indeterminate Cytology. Frontiers in Endocrinology, 2021, 12, 613727.	1.5	5
11	Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel missense mutation in AVP gene in a large Italian kindred. Endocrine, 2021, 74, 188-192.	1.1	3
12	Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical―and a "cytological―series. Journal of Endocrinological Investigation, 2021, , 1.	1.8	3
13	Improvement of Overall Survival Using TKIs as Salvage Therapy in Advanced Thyroid Carcinoma: Real-Life Data on a Single Center Experience. Journal of Clinical Medicine, 2021, 10, 384.	1.0	4
14	Long-Term Clinical Outcome in Familial and Sporadic Papillary Thyroid Carcinoma. European Thyroid Journal, 2020, 9, 213-220.	1.2	8
15	Should familial disease be considered as a negative prognostic factor in micropapillary thyroid carcinoma?. Journal of Endocrinological Investigation, 2019, 42, 1205-1213.	1.8	12
16	Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. Journal of Endocrinological Investigation, 2018, 41, 1029-1035.	1.8	24
17	Prospective Validation of ATA and ETA Sonographic Pattern Risk of Thyroid Nodules Selected for FNAC. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2362-2368.	1.8	19
18	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	1.8	11

MARCO CAPEZZONE

#	Article	IF	CITATIONS
19	Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1327-E1331.	1.8	31
20	Lack of Mutations of the Telomerase RNA Component in Familial Papillary Thyroid Cancer with Short Telomeres. Thyroid, 2012, 22, 363-368.	2.4	15
21	Telomere Length in Neoplastic and Nonneoplastic Tissues of Patients with Familial and Sporadic Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1852-E1856.	1.8	28
22	Telomerase and the endocrine system. Nature Reviews Endocrinology, 2011, 7, 420-430.	4.3	12
23	Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer. Thyroid Research, 2010, 3, 4.	0.7	25
24	Impact of Proto-Oncogene Mutation Detection in Cytological Specimens from Thyroid Nodules Improves the Diagnostic Accuracy of Cytology. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1365-1369.	1.8	295
25	Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth?. Journal of Endocrinological Investigation, 2010, 33, 576-578.	1.8	1
26	Telomeres and Thyroid Cancer. Current Genomics, 2009, 10, 526-533.	0.7	16
27	Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocrine-Related Cancer, 2008, 15, 1075-1081.	1.6	119
28	Short Telomeres, Telomerase Reverse Transcriptase Gene Amplification, and Increased Telomerase Activity in the Blood of Familial Papillary Thyroid Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3950-3957.	1.8	80
29	Limited Value of Repeat Recombinant Human Thyrotropin (rhTSH)-Stimulated Thyroglobulin Testing in Differentiated Thyroid Carcinoma Patients with Previous Negative rhTSH-Stimulated Thyroglobulin and Undetectable Basal Serum Thyroglobulin Levels. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 76-81.	1.8	112
30	Clinical Features and Therapeutic Implication of Papillary Thyroid Microcarcinoma. Thyroid, 2007, 17, 1085-1092.	2.4	98
31	Increasing incidence of thyroid cancer in Basilicata: An Italian study. Journal of Endocrinological Investigation, 2007, 30, 507-512.	1.8	9
32	Skin Metastases from Anaplastic Thyroid Carcinoma. Thyroid, 2006, 16, 513-514.	2.4	5
33	Activation of Nicotinamide N-Methyltransferase Gene Promoter by Hepatocyte Nuclear Factor-1Î <sup>2</sup> in Human Papillary Thyroid Cancer Cells. Molecular Endocrinology, 2005, 19, 527-539.	3.7	58
34	Disappearance of Humoral Thyroid Autoimmunity after Complete Removal of Thyroid Antigens. Annals of Internal Medicine, 2003, 139, 346.	2.0	307
35	Diagnostic 131-lodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1499-1501.	1.8	260
36	Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness. Surgery, 2002, 132, 1070-1074.	1.0	199

MARCO CAPEZZONE

#	Article	IF	CITATIONS
37	RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. European Journal of Endocrinology, 2001, 145, 599-604.	1.9	50
38	Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. European Journal of Endocrinology, 2001, 144, 5-11.	1.9	92
39	Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5686-5690.	1.8	167
40	Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients. Thyroid, 2001, 11, 877-881.	2.4	140
41	Use of Surgical Gamma Probe for the Detection of Lymph Node Metastases in Differentiated Thyroid Cancer. Tumori, 2000, 86, 367-369.	0.6	12